Fourpath Capital Management LLC Reduces Stake in Gilead Sciences, Inc. $GILD

Key Points

• Fourpath Capital Management LLC has reduced its stake in Gilead Sciences, Inc. by 35%, now holding 6,778 shares worth approximately $751,000.
• Shares of Gilead Sciences are currently priced at $116.74, with a market cap of $144.85 billion and a reported P/E ratio of 23.26.
• Gilead Sciences announced a quarterly dividend of $0.79 per share, reflecting an annualized yield of 2.7%.

Fourpath Capital Management LLC reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 35.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,778 shares of the biopharmaceutical company's stock after selling 3,645 shares during the period. Fourpath Capital Management LLC's holdings in Gilead Sciences were worth $751,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC grew its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC purchased a new position in shares of Gilead Sciences in the fourth quarter valued at about $215,000. GAMMA Investing LLC lifted its position in shares of Gilead Sciences by 24.9% in the first quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company's stock valued at $2,550,000 after acquiring an additional 4,532 shares in the last quarter. Simplicity Wealth LLC purchased a new position in shares of Gilead Sciences in the first quarter valued at about $483,000. Finally, Integrated Advisors Network LLC lifted its position in shares of Gilead Sciences by 7.6% in the first quarter. Integrated Advisors Network LLC now owns 8,138 shares of the biopharmaceutical company's stock worth $912,000 after buying an additional 574 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

Shares of GILD opened at $116.74 on Friday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a one year low of $84.17 and a one year high of $121.83. The stock has a 50-day moving average of $114.57 and a two-hundred day moving average of $110.19. The stock has a market cap of $144.85 billion, a P/E ratio of 23.26, a P/E/G ratio of 0.80 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the prior year, the firm earned $2.01 EPS. The business's revenue for the quarter was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences's dividend payout ratio is currently 62.95%.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Royal Bank Of Canada boosted their target price on Gilead Sciences from $98.00 to $100.00 and gave the stock a "sector perform" rating in a research report on Wednesday. Truist Financial raised Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Dbs Bank raised Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Weiss Ratings reissued a "buy (b)" rating on shares of Gilead Sciences in a research note on Wednesday. Finally, Daiwa America raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and an average target price of $118.08.

Insider Activity

In related news, insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the completion of the sale, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. This represents a 2.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares of the company's stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock worth $9,402,130 over the last three months. Insiders own 0.27% of the company's stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.